Cardioprotective Effects of PARP Inhibitors: A Re-Analysis of a Meta-Analysis and a Real-Word Data Analysis Using the FAERS Database

Cardioprotective Effects of PARP Inhibitors: A Re-Analysis of a Meta-Analysis and a Real-Word Data Analysis Using the FAERS Database

<b>Objective:</b> This study aimed to assess the potential of PARP inhibitors to prevent cardiotoxicity. <b>Methods:</b> First, a re-analysis and update of a previously published study was conducted. Additional searches were conducted of the PubMed and Cochrane Central Regist...

Full description

Bibliographic Details
Main Authors:	Ja-Young Han, Young-Eun Seo, Jae-Hee Kwon, Jae Hyun Kim, Myeong Gyu Kim
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Journal of Clinical Medicine
Subjects:	PARP inhibitors cardiac adverse events combination meta-analysis FAERS
Online Access:	https://www.mdpi.com/2077-0383/13/5/1218

Similar Items

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
by: Jeanne M. Schilder, et al.
Published: (2023-08-01)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
by: Yamin Shu, et al.
Published: (2023-02-01)

Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database
by: Feng Huang, et al.
Published: (2024-03-01)

Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database
by: Zhao Li, et al.
Published: (2024-03-01)

Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database
by: Ying Jiang, et al.
Published: (2024-04-01)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024-03-01)

Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database
by: Shihao Chen, et al.
Published: (2024-03-01)

Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
by: Yun Li, et al.
Published: (2024-03-01)

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
by: Xiaojiang Tian, et al.
Published: (2022-03-01)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022-11-01)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
by: Lin Zhang, et al.
Published: (2023-11-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

PARP inhibitor-related haemorrhages: What does the real-world study say?
by: Shiyan Wang, et al.
Published: (2023-02-01)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023-12-01)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023-07-01)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseResearch in context
by: Chaozheng Zhou, et al.
Published: (2023-05-01)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023-10-01)

Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database
by: Heenam Seo, et al.
Published: (2023-01-01)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
by: Wensheng Liu, et al.
Published: (2023-11-01)

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)
by: Santa Cirmi, et al.
Published: (2020-03-01)

Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS
by: Shu Tang, et al.
Published: (2022-10-01)

Evaluation of adverse events of CDK4/6 inhibitors: a real-world study based on the FAERS database
by: SHE Youjun, GUO Zihan, ZHANG Zhongwei, DU Qiong
Published: (2023-10-01)

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
by: Fan Zou, et al.
Published: (2024-02-01)

Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis
by: Xiyuan Zhou, et al.
Published: (2024-01-01)

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
by: Shu Y, et al.
Published: (2022-06-01)

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database
by: Yamin Shu, et al.
Published: (2022-09-01)

Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years
by: Ping Zhang, et al.
Published: (2022-08-01)

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
by: Xiang Zhou, et al.
Published: (2021-12-01)

Opioids and frequency counts in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database: a quantitative view of the epidemic
by: Veronin MA, et al.
Published: (2019-08-01)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
by: Chenxin Chen, et al.
Published: (2021-02-01)

Pneumatosis intestinalis post steroid use in a patient with immune-related adverse events: Case report, literature review and FAERS analysis
by: Tingting Zhang, et al.
Published: (2023-03-01)

Mining and visualizing high-order directional drug interaction effects using the FAERS database
by: Xiaohui Yao, et al.
Published: (2020-03-01)

Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS)
by: A. K. Ali
Published: (2013-04-01)

The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database
by: Huaju Yang, et al.
Published: (2023-11-01)

Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data
by: Greta Santi Laurini, et al.
Published: (2022-12-01)

Characteristics and Spectrum of Cardiotoxicity Induced by Various Antipsychotics: A Real-World Study From 2015 to 2020 Based on FAERS
by: Luyao He, et al.
Published: (2022-02-01)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023-02-01)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
by: Yan Wu, et al.
Published: (2023-08-01)

Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
by: Tigran Makunts, et al.
Published: (2022-01-01)

Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015
by: Alshammari TM, et al.
Published: (2018-05-01)